Three cases of herpes zoster radiculitis in MS patients treated with natalizumab

• DOI: 10.1016/j.msard.2016.07.012
• Publication Date: 2016-07-26T09:40:33Z
• Authors: Bassem I. Yamout; Nuhad Abou Zeid; Ali J. Taha; Maya M. Zeineddine; Samia J. Khoury
• Keywords: Young Adult; 03 medical and health sciences; Multiple Sclerosis, Relapsing-Remitting; 0302 clinical medicine; Natalizumab; Humans; Immunologic Factors; Female; Middle Aged; Herpes Zoster; 3. Good health

Natalizumab was the first FDA-approved monoclonal antibody for the treatment of multiple sclerosis (MS). We report on 3 natalizumab-treated patients who developed herpes zoster infections. In addition to progressive multifocal leukoencephelopathy, other opportunistic infections have been rarely reported during Natalizumab treatment. We believe that clinicians need heightened awareness of these infections in view of the risks of serious complications.